Barclays analyst Saket Kalia raised the firm’s price target on Hinge Health (HNGE) to $65 from $62 and keeps an Overweight rating on the shares. The company reported better Q3 billings driven by expanding yields, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HNGE:
- Hinge Health Reports Strong Q3 2025 Financial Results
- Hinge Health: Strong Financial Performance and Growth Potential Amidst Rising Demand for Digital MSK Solutions
- Hinge Health reports Q3 EPS (2c) vs 1c last year
- Hinge Health sees Q4 revenue $155M-$157M, consensus $145.42M
- Hinge Health raises FY25 revenue view to $572M-$574M from $548M-$552M